PANTHER. A Randomized Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel (dtEC→dtT) Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel (FEC→T) in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients

Trial Profile

PANTHER. A Randomized Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel (dtEC→dtT) Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel (FEC→T) in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Fluorouracil
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PANTHER; SOS
  • Most Recent Events

    • 12 Sep 2017 Results (n=1428) of analysis evaluating relationship between toxicity items and items in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire presented at the 42nd European Society for Medical Oncology Congress
    • 10 Jun 2017 Biomarkers information updated
    • 08 Nov 2016 Results published in the JAMA: the Journal of the American Medical Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top